CAR-T cell therapy for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new treatment using your own immune cells (CAR-T cells) to target a protein called CSPG4 found on head and neck cancer cells. It is for people whose cancer has come back or not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You must have a type of head and neck cancer (squamous cell carcinoma of the oral cavity, throat, or voice box) that has spread or come back
- You must be generally active and able to care for yourself (Karnofsky score above 60%)
- You cannot have serious heart disease, a recent stroke, or a history of severe allergic reaction to certain chemotherapy drugs (cyclophosphamide or fludarabine)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells, modified to target a protein called B7-H3 on triple-negative breast cancer cells. It may help if other treatments haven't worked.
This study tests a new type of CAR-T cell therapy that targets a protein called Trop2 found on some head and neck cancer cells. It's for people who have tried standard treatments and need a new option.
This study focuses on testing a personalized immune therapy (made from your tumor-fighting T cells) for people with head and neck cancer. It may help patients whose cancer is new and untreated or whose cancer has come back or is not responding to standard options.
This trial tests a new type of cell therapy using natural killer cells (immune cells) that are designed to recognize and attack head and neck cancer cells. The therapy targets two specific proteins (EGFR and HER2) found on cancer cells and is for patients whose cancer has returned or spread despite previous treatments.
This trial tests a CAR-T cell therapy for people with certain types of blood cancer that have come back or not responded to standard treatment. The therapy targets specific markers on cancer cells to help your immune system fight the disease.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers on cancer cells at once. The goal is to help patients with advanced solid tumors where standard treatments have stopped working or aren't an option.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.